Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Tanke Biosciences Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2009
FY2011
FY2011
FY2012
Revenue
20.1
23.8
28.6
Cost of revenue
12.7
15.1
18.6
Gross profit
7.4
8.77
9.94
Research and development
0.25
0.29
General and administrative
0.83
4.49
2.57
Operating income
4.37
1.74
4.53
Interest expense
0.1
1.36
1.45
Interest income
0
0.1
0.3
Pre-tax income
4.28
-2.45
0.6
Income tax
0.58
0.68
0.83
Net income to minority interests
0.96
0
-0.02
Net income
2.58
2.74
-3.14
-0.21
EBITDA
4.51
2.14
5.17
EPS, basic
0.34
-0.24
-0.02
EPS, diluted
0.34
-0.24
-0.02
Shares, basic (weighted)
10.8
13.1
13.3
Shares, diluted (weighted)
10.8
13.1
13.3
Balance sheet
FY2009
FY2011
FY2011
FY2012
Cash and equivalents
1.82
2.22
7.7
6.17
Receivables
1.77
1.92
1.99
Inventory
1.35
1.19
1.41
Other current assets
0.16
0.91
0.13
Total current assets
7.67
18.9
22.4
Property, plant and equipment
1.55
4.77
4.81
Intangible assets
0.29
0.84
1.24
Other non-current assets
0
0.33
0.13
Total assets
13.3
24.9
28.8
Accounts payable
0.6
0.78
0.65
Short-term debt
0.91
0.79
1.27
Total current liabilities
2.41
3.55
12.1
Long-term debt
0.45
0.63
0.79
Total liabilities
2.93
9.03
12.9
Total debt
1.36
1.41
2.06
Paid-in capital
1.42
12.2
12.2
Retained earnings
5.83
2.7
2.49
Other comprehensive income
0.53
0.55
0.66
Shareholders' equity
8.16
15.9
15.8
Minority interests
2.17
0
0.17
Total equity
6.44
10.3
15.9
15.9
Total liabilities and equity
13.3
24.9
28.8
Shares outstanding
10.8
13.3
13.3
Cash flow statement
FY2009
FY2011
FY2011
FY2012
Net income
2.58
3.69
-3.14
-0.23
Depreciation and amortization
0.14
0.4
0.64
Stock-based compensation
0
2.49
Deferred income tax
-0.03
0.02
Change in receivables
-0.24
-0.17
-0.17
Change in inventory
-0.33
0.17
-0.23
Change in payables
0.56
0.15
-0.14
Cash from operations
4.38
3.65
-1.18
Capital expenditures
-0.08
-0.7
-0.86
Cash from investing
-2.82
-3.67
-1.53
Cash from financing
-1.22
5.82
1.12
Exchange rate effect
0.06
-0.32
0.06
Net change in cash
0.4
5.48
-1.53
Free cash flow
4.31
2.95
-2.04
Interest paid
0.1
0.65
0.63
Income taxes paid
0.18
0.25
0.35
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2013; growth uses fiscal years. Valuation uses the share price of $0.01 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
32.3%
Gross profit / revenue.
Operating margin
-0.2%
Operating income / revenue.
EBITDA margin
2.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-6.3%
Pre-tax income / revenue.
Net margin
-7.1%
Net income / revenue.
FCF margin
-26.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-15.8%
Cash from operations / revenue.
Return on equity (ROE)
-10.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.7%
Net income / average total assets.
Return on invested capital (ROIC)
-0.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Capex / revenue
10.8%
Capital expenditures / revenue.
D&A / revenue
2.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
19.8%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
13.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Operating income growth, 1y
160.6%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
141.6%
EBITDA vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-132.4%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-169.1%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-0.6%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
15.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
1.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.61x
Current assets / current liabilities.
Quick ratio
0.64x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.41x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.12x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
6.5%
Total debt / total assets.
Liabilities / assets
45.5%
Total liabilities / total assets.
Net debt
-$3.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
-6.71x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.12
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.72
Revenue / diluted weighted shares.
FCF per share
-$0.46
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.27
Cash from operations / diluted weighted shares.
Book value per share
$1.17
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.01x
Market cap / revenue.
P/B
0.01x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.01x
Market cap / tangible book value, when positive.
FCF yield
-4,598.0%
Free cash flow / market cap.
Earnings yield
-1,231.0%
Net income / market cap (the inverse of P/E).
What was Tanke Biosciences Corp's revenue in fiscal 2012?
Tanke Biosciences Corp reported revenue of $28.6M for fiscal 2012, 19.8% higher than the year before.
Was Tanke Biosciences Corp profitable in fiscal 2012?
No. It reported a net loss of $210.2K.
How much free cash flow did Tanke Biosciences Corp generate in fiscal 2012?
Cash from operations of $1.2M minus capital expenditures of $856.4K left free cash flow of -$2.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.